Dr. Hamid on Potential Combinations With Docetaxel in mHSPC Subtypes

Video

In Partnership With:

Anis Hamid, MBBS, discusses potential combination with docetaxel in metastatic hormone-sensitive prostate cancer subtypes.

Anis Hamid, MBBS, genitourinary oncology research fellow, Dana-Farber Cancer Institute, discusses potential combinations with docetaxel in metastatic hormone-sensitive prostate cancer (mHSPC) subtypes.

Patients with luminal B mHSPC appear to benefit from docetaxel, says Hamid.

However, it is not yet understood whether the luminal B and basal subtypes respond similarly to available hormonal therapies such as abiraterone acetate (Zytiga), enzalutamide (Xtandi), and apalutamide (Erleada) as classic mHSPC, explains Hamid.

These agents are being investigated in prospective clinical trials for this patient population, says Hamid.

Additionally, the RNA profiling data from those studies may shed light on the utility of hormonal therapy in these subtypes of mHSPC, concludes Hamid.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD